Canaccord initiated coverage of Alterity Therapeutics with a Speculative Buy rating and $A1.6c price target. Alterity is developing ATH434 for the treatment of synucleinopathy-driven neurodegenerative diseases such as multiple system atrophy and Parkinson's disease, the analyst tells investors in a research note. The firm says ATH434 addresses an unmet need.
